ArticleRSC advances2026
Structure-based design and optimization of cyclic peptide ligands targeting delta-like ligand 3.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delta-like ligand 3 (DLL3) is a promising theranostic target due to its high and specific overexpression in small cell lung cancer and other neuroendocrine tumors. To develop novel targeting agents, we designed and synthesized a series of cyclic peptides targeting DLL3. We optimized three key residues: Trp9 and Gly4 on the PepSP1171 core scaffold, and Val4 on PepSP1214, through systematic amino acid substitution and incorporation of non-natural residues. This approach yielded six high-affinity peptides with dissociation constants (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.